Table 5.

Targeting cell metabolism for cancer treatment

Targets	Drugs	Clinical phase	Conditions	Sponsor	Gov identifier
Tyrosine kinase	PLX3397	1	Prostate adenocarcinoma	Barbara Ann Karmanos Cancer Institute	NCT02472275
Cholesterol	Tesco	Not applicable	Breast cancer	University of Leeds	NCT04147767
mTOR	Sirolimus	1/2	Pancreatic cancer	Second Affiliated Hospital, School of Medicine, Zhejiang University	NCT03662412
Glucose metabolism	Metformin	2	Breast cancer	Oxford University Hospitals NHS Trust	NCT01266486
		1	Head and neck squamous cell cancer	Sidney Kimmel Cancer Center at Thomas Jefferson University	NCT02083692
		1	Cancer of head and neck	West Virginia University	NCT02402348
		2	Lung cancer	M.D. Anderson Cancer Center	NCT02285855
		1	Endometrial cancer	M.D. Anderson Cancer Center	NCT01205672
	2-DG	1/2	Prostate cancer	Rutgers, The State University of New Jersey	NCT00633087
			Intracranial neoplasms		NCT00247403
			Neoplasm metastasis
PPARγ	Rosiglitazone	2	Melanoma	Dan Zandberg	NCT04114136
			Nsclc
			Hepatocellular carcinoma
	Dichloroacetate	1	Head and neck cancer	Daniel T. Chang	NCT01163487
	Pioglitazone	2	Cancer of the pancreas	University of Texas Southwestern Medical Center	NCT01838317
Cholesterol	Evolocumab	1	Pancreatic ductal adenocarcinoma	CHU de Quebec-Universite Laval	NCT04862260
		1	Glioblastoma	Duke University	NCT04937413
	Atorvastatin		Pancreatic cancer
	Ezetimibe		Pancreas cancer
			Metastatic cancer
HMG-CoA reductase	Rosuvastatin	4	Prostate cancer metastatic	National Cancer Institute, Egypt	NCT04776889
Arginase	INCB001158	1/2	Metastatic cancer	Incyte Corporation	NCT02903914
			Solid tumours
			Colorectal cancer
			Gastric cancer
		1	Advanced solid tumours	Advanced solid tumours	NCT03910530
			Advanced solid tumours
		1/2	Biliary tract cancer	Incyte Corporation	NCT03314935
			Colorectal cancer
			Endometrial cancer
		1/2	Solid tumours	Incyte Corporation	NCT03361228